Although concomitant FLT3-ITD mutations may provide a therapeutic target, it is unclear whether FLT3 inhibitor maintenance therapy provides a survival benefit in AML patients with DEK-NUP214 transcripts after allo-HSCT.[37] In our study, one patient still relapsed despite the use of sorafenib as maintenance therapy. Here, FLT3 is linked to acute myeloid leukemia.